裸盖菇素辅助心理治疗减少酒精使用障碍患者重度饮酒天数
这项双盲随机临床试验纳入95名酒精依赖成人,比较裸盖菇素与活性安慰剂(苯海拉明)联合心理治疗的效果。结果显示,32周内裸盖菇素组重度饮酒天数百分比为9.7%,显著低于苯海拉明组的23.6%,平均差异13.9%(95%CI 3.0-24.7;裸盖菇素组未发生严重不良事件。
要点
- 裸盖菇素组平均每日酒精消耗量(标准杯/天)也低于苯海拉明组。
- 接受裸盖菇素的参与者中未发生严重不良事件。
核心结论
- 裸盖菇素联合心理治疗在减少重度饮酒天数方面优于活性安慰剂联合心理治疗。
- 结果为裸盖菇素辅助治疗酒精使用障碍的进一步研究提供了支持。
研究设计与样本
- 双盲随机临床试验,在美国2个学术中心开展,2014年3月12日至2020年3月19日从社区招募参与者。
- 纳入25至65岁、符合DSM-IV酒精依赖诊断且筛查前30天内至少4天重度饮酒的成人。
- 共95名参与者随机分配至裸盖菇素组(49人)或苯海拉明组(46人),93人至少接受1剂研究药物并纳入主要结局分析。
- 参与者接受12周结构化心理治疗(动机增强疗法和认知行为疗法),并在第4周和第8周接受2次全天药物 sessions。
- 主要结局为首次给药后32周双盲期内重度饮酒天数百分比,采用时间线回溯访谈评估。
主要发现
- 裸盖菇素组平均每日酒精消耗量(标准杯/天)也低于苯海拉明组。
- 接受裸盖菇素的参与者中未发生严重不良事件。
关键数值与推荐
- 研究药物剂量:裸盖菇素25 mg/70 kg vs 苯海拉明50 mg(第一次 session);裸盖菇素25-40 mg/70 kg vs 苯海拉明50-100 mg(第二次 session)。
- 主要结局分析采用多变量重复测量方差分析,对比两组在首次给药后32周内的重度饮酒天数百分比。
临床怎么用
- 对于符合条件的酒精使用障碍成人,裸盖菇素联合心理治疗可能减少重度饮酒天数。
- 治疗需在结构化心理治疗(动机增强疗法和认知行为疗法)背景下进行。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Although classic psychedelic medications have shown promise in the treatment of alcohol use disorder (AUD), the efficacy of psilocybin remains unknown. OBJECTIVE: To evaluate whether 2 administrations of high-dose psilocybin improve the percentage of heavy drinking days in patients with AUD undergoing psychotherapy relative to outcomes observed with active placebo medication and psychotherapy. DESIGN, SETTING, AND PARTICIPANTS: In this double-blind randomized clinical trial, participants were offered 12 weeks of manualized psychotherapy and were randomly assigned to receive psilocybin vs diphenhydramine during 2 day-long medication sessions at weeks 4 and 8. Outcomes were assessed over the 32-week double-blind period following the first dose of study medication. The study was conducted at 2 academic centers in the US. Participants were recruited from the community between March 12, 2014, and March 19, 2020. Adults aged 25 to 65 years with a DSM-IV diagnosis of alcohol dependence and at least 4 heavy drinking days during the 30 days prior to screening were included. Exclusion criteria included major psychiatric and drug use disorders, hallucinogen use, medical conditions that contraindicated the study medications, use of exclusionary medications, and current treatment for AUD. INTERVENTIONS: Study medications were psilocybin, 25 mg/70 kg, vs diphenhydramine, 50 mg (first session), and psilocybin, 25-40 mg/70 kg, vs diphenhydramine, 50-100 mg (second session). Psychotherapy included motivational enhancement therapy and cognitive behavioral therapy. MAIN OUTCOMES AND MEASURES: The primary outcome was percentage of heavy drinking days, assessed using a timeline followback interview, contrasted between groups over the 32-week period following the first administration of study medication using multivariate repeated-measures analysis of variance. RESULTS: A total of 95 participants (mean [SD] age, 46 [12] years; 42 [44.2%] female) were randomized (49 to psilocybin and 46 to diphenhydramine). One participant (1.1%) was American Indian/Alaska Native, 3 (3.2%) were Asian, 4 (4.2%) were Black, 14 (14.7%) were Hispanic, and 75 (78.9%) were non-Hispanic White. Of the 95 randomized participants, 93 received at least 1 dose of study medication and were included in the primary outcome analysis. Percentage of heavy drinking days during the 32-week double-blind period was 9.7% for the psilocybin group and 23.6% for the diphenhydramine group, a mean difference of 13.9%; (95% CI, 3.0-24.7; F1,86 = 6.43; P = .01). Mean daily alcohol consumption (number of standard drinks per day) was also lower in the psilocybin group. There were no serious adverse events among participants who received psilocybin. CONCLUSIONS AND RELEVANCE: Psilocybin administered in combination with psychotherapy produced robust decreases in percentage of heavy drinking days over and above those produced by active placebo and psychotherapy. These results provide support for further study of psilocybin-assisted treatment for AUD. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02061293.
引用
- Bogenschutz MP, Ross S, Bhatt S, et al. Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2022. PMID: 36001306. doi:10.1001/jamapsychiatry.2022.2096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。